BCL2L1 and gastric carcinoma: After TGF-β1 treatment, researchers found that TGF-β induced SMAD-dependent binding between the proapoptotic effector BIM and BCL-XL in gastric carcinoma cell lines [40] and a decrease in BCL-XL expression followed by activation of the apoptosis proteins caspase-9 and caspase-3 in human hepatoma cells (HuH-7) [41].